Topic: Strategy

Latest content

The world’s leading IP strategists named

The 2021 edition of the IAM Strategy 300 has been published and identifies gamechangers working inside corporations, aggregators, service providers, research institutions and universities, among others

31 August 2021

PTAB proceedings are a vital tool in the biologics space, despite low usage rates

While generic enthusiasm for IPRs has waned, administrative challenges are of growing importance to biosimilar producers

31 August 2021

First FDA interchangeable approval is a potential gamechanger for biosimilar patent strategy

Move could change the shape of the healthcare market and herald a rewrite of the life sciences IP playbook

27 August 2021

As solar patent war rolls on, Chinese panel leader says it has seen off biggest threats

JinKo Solar explains how a Sino-Korean patent battle has played out so far, revealing big differences in US and German results

27 August 2021

IAM parent company acquires market-leading US patent litigation data and analytics firm

Austin-based Docket Navigator - which also covers trademarks, antitrust and other legal practice areas - becomes a Law Business Research company

25 August 2021

AbbVie looks set to recreate Humira patent thicketing success following Imbruvica victory

District of Delaware decision clears the way for the company to generate billions of dollars in sales well into the next decade

24 August 2021

Legal challenges to the PTAB’s NHK-Fintiv discretionary denial regime mount

Life sciences companies are among those leading the way in going to court to get the current rules struck down

20 August 2021

How the covid-19 pandemic has transformed the IP legal landscape

The Long Read: Top private practice partners based in Australia reflect on what it has taken to captain their firms through the events of the last 18 months and look at the ways in which the significant upheavals have affected the IP services industry

18 August 2021

Panasonic is the latest HEVC heavy hitter to join Access Advance

Japanese electronics giant becomes first member of rival platform Velos Media to make its assets available through Access Advance

16 August 2021

$235 million CAFC decision creates confusion around skinny-label generics, says dissenting judge

The Federal Circuit hands down its second ruling in the carvedilol dispute between Teva and GSK, following widespread concern over its first

13 August 2021

Get unlimited access to all IAM content